Supreme Court drug case could restrict development: Lilly, other firms want research exemption confirmed

The U.S. Supreme Court will hear arguments April 20 in a case that Eli Lilly and Co. and other pharmaceutical corporations say could restrict the development of new drugs. The dispute stems from a June 2003 decision by the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. The panel affirmed a district court's finding that Merck KGaA in Germany infringed upon four of New Jersey-based Integra LifeSciences Holdings Corp.'s licensed patents. At issue is whether pharmaceutical companies...

 

You have accessed IBJ.com Premium online content

IBJ.com Premium online content is identified by locked premium or unlocked premium symbol to the right of the headline. Access to all IBj.com Premium online content requires a paid IBJ.com Premium subscription and the subscriber to be logged in using their email and password. See subscription options below.

Log In if you are a subscriber to IBJ.com Premium Online

...Or choose the IBJ subscription that's right for you:

7 Day Subscription

$4.95 per week

IBJ.com
Premium online

Order Now
   

1 Year Subscription

$1.25 per week

IBJ.com
Premium online

Order Now
 

1 Year Subscription

$1.52 per week

IBJ Print
only

Order Now

 

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT